Serotonin (5-HT) is synthesized in dorsal and median raphe nuclei and acts via seven receptor subtypes to regulate mood, sleep, appetite, and sexual function. Serotonergic neurons fire according to sleep-wake cycles and arousal state. SSRIs block reuptake, increasing synaptic 5-HT. Serotonin dysfunction is implicated in depression, anxiety, and OCD.
Map raphe projections to cortex, limbic system, and brainstem. Compare 5-HT receptor distribution with behavioral functions.
Low serotonin causes depression—the relationship is more complex. SSRIs directly make people happy—they shift long-term network properties.
From your understanding of serotonin's role in emotion regulation and the basics of synaptic transmission, you know that neurotransmitters modulate emotional states and that synaptic signaling involves release, receptor binding, and reuptake. The serotonin system (also called the 5-HT system, from 5-hydroxytryptamine) is one of the brain's most widespread neuromodulatory networks. Despite originating from a remarkably small number of neurons — roughly 300,000 in the human brain, clustered in the raphe nuclei of the brainstem — serotonergic axons project to virtually every region of the central nervous system, giving this tiny population an outsized influence on brain function.
Serotonin is synthesized from the amino acid tryptophan in a two-step process: tryptophan hydroxylase (the rate-limiting enzyme) converts tryptophan to 5-hydroxytryptophan, which is then decarboxylated to serotonin. The raphe nuclei are divided into two major groups with distinct projection targets. The dorsal raphe projects primarily to the cerebral cortex, basal ganglia, and limbic structures (amygdala, hippocampus), influencing mood, cognition, and reward processing. The median raphe projects heavily to the hippocampus and septum, playing a larger role in memory and anxiety regulation. Serotonergic neurons have a distinctive firing pattern: they fire slowly and regularly during waking, decrease during quiet rest, and fall nearly silent during REM sleep — making serotonin a signal of wakefulness and behavioral arousal rather than a simple "happiness chemical."
What makes the serotonin system extraordinarily complex is its receptor diversity. There are seven families of 5-HT receptors (5-HT₁ through 5-HT₇), comprising at least 14 distinct subtypes. All except 5-HT₃ (which is a ligand-gated ion channel) are metabotropic GPCRs, each coupled to different intracellular signaling cascades. The 5-HT₁A receptor is inhibitory and serves as both an autoreceptor on raphe neurons (providing negative feedback to reduce serotonin release) and a postsynaptic receptor in the hippocampus and cortex. The 5-HT₂A receptor is excitatory and densely expressed in the cortex — it is the primary target of psychedelic drugs like LSD and psilocybin. The 5-HT₃ receptor mediates fast excitation in the gut and brainstem vomiting centers. This receptor diversity means that serotonin does not have a single "effect" — it can excite or inhibit, act fast or slow, and produce completely different outcomes depending on which receptor subtype is present on the target neuron.
SSRIs (selective serotonin reuptake inhibitors), the most commonly prescribed antidepressants, work by blocking the serotonin transporter (SERT) that normally clears serotonin from the synaptic cleft back into the presynaptic terminal. This increases the concentration and duration of serotonin signaling at postsynaptic receptors. However, the therapeutic effect of SSRIs takes 2-4 weeks to develop, even though serotonin levels rise within hours of the first dose. This delay reveals that SSRIs do not work simply by "increasing serotonin." Instead, the sustained elevation of synaptic serotonin gradually triggers downstream adaptations: 5-HT₁A autoreceptors desensitize (removing the brake on serotonin release), postsynaptic receptor expression remodels, and neurotrophic factors like BDNF increase, promoting synaptic plasticity and neurogenesis in the hippocampus. The therapeutic effect emerges from this slow network-level reorganization, not from the immediate pharmacological action — which is why the simplistic "chemical imbalance" narrative of depression, while useful as a metaphor, does not capture the actual neurobiology.